# Onto Innovation Inc.: financial statements, quarterly

ONTO · NYSE · CIK 704532 · [Technology](/sectors/technology.md) · fiscal year ends Dec 26

Pages: [Overview](/companies/onto.md) · [Financials](/companies/onto/financials.md) · [Filings](/companies/onto/filings.md) · [Insiders](/companies/onto/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/onto/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [207](/filings/0000950170-24-119668.md) | [219 d](/filings/0001193125-26-066937.md) | [229](/filings/0000950170-25-066934.md) | [242](/filings/0000950170-25-105161.md) | [252](/filings/0001193125-25-270040.md) | [264 d](/filings/0001193125-26-066937.md) | [267](/filings/0001193125-26-206707.md) | [254](/filings/0001193125-26-338401.md) | [218](/filings/0001193125-25-270040.md) | [267 d](/filings/0001193125-26-066937.md) | [292](/filings/0001193125-26-206707.md) | [343](/filings/0001193125-26-338401.md) |
| Cost of revenue | $m | [100](/filings/0000950170-24-119668.md) | [111 d](/filings/0001193125-26-066937.md) | [111](/filings/0000950170-25-066934.md) | [114](/filings/0000950170-25-105161.md) | [116](/filings/0001193125-25-270040.md) | [132 d](/filings/0001193125-26-066937.md) | [123](/filings/0001193125-26-206707.md) | [131](/filings/0001193125-26-338401.md) | [108](/filings/0001193125-25-270040.md) | [143 d](/filings/0001193125-26-066937.md) | [146](/filings/0001193125-26-206707.md) | [160](/filings/0001193125-26-338401.md) |
| Gross profit | $m | [107](/filings/0000950170-24-119668.md) | [108 d](/filings/0001193125-26-066937.md) | [118](/filings/0000950170-25-066934.md) | [128](/filings/0000950170-25-105161.md) | [136](/filings/0001193125-25-270040.md) | [132 d](/filings/0001193125-26-066937.md) | [143](/filings/0001193125-26-206707.md) | [122](/filings/0001193125-26-338401.md) | [111](/filings/0001193125-25-270040.md) | [124 d](/filings/0001193125-26-066937.md) | [146](/filings/0001193125-26-206707.md) | [183](/filings/0001193125-26-338401.md) |
| Research and development | $m | [26.1](/filings/0000950170-24-119668.md) | [24.0 d](/filings/0001193125-26-066937.md) | [26.6](/filings/0000950170-25-066934.md) | [27.0](/filings/0000950170-25-105161.md) | [28.3](/filings/0001193125-25-270040.md) | [32.0 d](/filings/0001193125-26-066937.md) | [28.0](/filings/0001193125-26-206707.md) | [35.3](/filings/0001193125-26-338401.md) | [32.5](/filings/0001193125-25-270040.md) | [36.2 d](/filings/0001193125-26-066937.md) | [35.1](/filings/0001193125-26-206707.md) | [38.9](/filings/0001193125-26-338401.md) |
| Operating income | $m | [34.0](/filings/0000950170-24-119668.md) | [28.2 d](/filings/0001193125-26-066937.md) | [42.7](/filings/0000950170-25-066934.md) | [48.8](/filings/0000950170-25-105161.md) | [53.1](/filings/0001193125-25-270040.md) | [42.5 d](/filings/0001193125-26-066937.md) | [63.1](/filings/0001193125-26-206707.md) | [32.2](/filings/0001193125-26-338401.md) | [23.7](/filings/0001193125-25-270040.md) | [13.9 d](/filings/0001193125-26-066937.md) | [33.5](/filings/0001193125-26-206707.md) | [63.6](/filings/0001193125-26-338401.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.8](/filings/0000950170-24-119668.md) | [3.5 d](/filings/0001193125-26-066937.md) | [4.0](/filings/0000950170-25-066934.md) | [4.3](/filings/0000950170-25-105161.md) | [8.0](/filings/0001193125-25-270040.md) | [2.5 d](/filings/0001193125-26-066937.md) | [7.6](/filings/0001193125-26-206707.md) | [5.8](/filings/0001193125-26-338401.md) | [3.8](/filings/0001193125-25-270040.md) | [9.0 d](/filings/0001193125-26-066937.md) | [4.3](/filings/0001193125-26-206707.md) | [8.4](/filings/0001193125-26-338401.md) |
| Net income | $m | [35.9](/filings/0000950170-23-062243.md) | [30.3 d](/filings/0001193125-26-066937.md) | [46.9](/filings/0000950170-25-066934.md) | [52.9](/filings/0000950170-25-105161.md) | [53.1](/filings/0001193125-25-270040.md) | [48.8 d](/filings/0001193125-26-066937.md) | [64.1](/filings/0001193125-26-206707.md) | [33.9](/filings/0001193125-26-338401.md) | [28.2](/filings/0001193125-25-270040.md) | [10.5 d](/filings/0001193125-26-066937.md) | [33.8](/filings/0001193125-26-206707.md) | [60.1](/filings/0001193125-26-338401.md) |
| Diluted EPS | $ per share | [0.73](/filings/0000950170-24-119668.md) | not reported | [0.94](/filings/0000950170-25-066934.md) | [1.07](/filings/0000950170-25-105161.md) | [1.07](/filings/0001193125-25-270040.md) | not reported | [1.30](/filings/0001193125-26-206707.md) | [0.69](/filings/0001193125-26-338401.md) | [0.57](/filings/0001193125-25-270040.md) | not reported | [0.67](/filings/0001193125-26-206707.md) | [1.21](/filings/0001193125-26-338401.md) |
| Basic EPS | $ per share | [0.73](/filings/0000950170-24-119668.md) | not reported | [0.95](/filings/0000950170-25-066934.md) | [1.07](/filings/0000950170-25-105161.md) | [1.07](/filings/0001193125-25-270040.md) | not reported | [1.30](/filings/0001193125-26-206707.md) | [0.69](/filings/0001193125-26-338401.md) | [0.58](/filings/0001193125-25-270040.md) | not reported | [0.68](/filings/0001193125-26-206707.md) | [1.22](/filings/0001193125-26-338401.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2026-01-03) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [207](/filings/0000950170-23-062243.md) | [234](/filings/0000950170-25-026729.md) | [191](/filings/0000950170-24-057270.md) | [173](/filings/0000950170-24-094193.md) | [189](/filings/0000950170-24-119668.md) | [213](/filings/0001193125-26-066937.md) | [204](/filings/0000950170-25-066934.md) | [217](/filings/0000950170-25-105161.md) | [603](/filings/0001193125-25-270040.md) | [346](/filings/0001193125-26-338401.md) | [252](/filings/0001193125-26-206707.md) | [1,253](/filings/0001193125-26-338401.md) |
| Current assets | $m | [1,221](/filings/0000950170-23-062243.md) | [1,283](/filings/0000950170-25-026729.md) | [1,333](/filings/0000950170-24-057270.md) | [1,385](/filings/0000950170-24-094193.md) | [1,458](/filings/0000950170-24-119668.md) | [1,478](/filings/0001193125-26-066937.md) | [1,469](/filings/0000950170-25-066934.md) | [1,494](/filings/0000950170-25-105161.md) | [1,545](/filings/0001193125-25-270040.md) | [1,268](/filings/0001193125-26-338401.md) | [1,320](/filings/0001193125-26-206707.md) | [2,642](/filings/0001193125-26-338401.md) |
| Total assets | $m | [1,862](/filings/0000950170-23-062243.md) | [1,910](/filings/0000950170-25-026729.md) | [1,953](/filings/0000950170-24-057270.md) | [2,005](/filings/0000950170-24-094193.md) | [2,073](/filings/0000950170-24-119668.md) | [2,117](/filings/0001193125-26-066937.md) | [2,115](/filings/0000950170-25-066934.md) | [2,140](/filings/0000950170-25-105161.md) | [2,187](/filings/0001193125-25-270040.md) | [2,368](/filings/0001193125-26-338401.md) | [2,396](/filings/0001193125-26-206707.md) | [3,699](/filings/0001193125-26-338401.md) |
| Current liabilities | $m | [136](/filings/0000950170-23-062243.md) | [148](/filings/0000950170-25-026729.md) | [147](/filings/0000950170-24-057270.md) | [148](/filings/0000950170-24-094193.md) | [145](/filings/0000950170-24-119668.md) | [170](/filings/0001193125-26-066937.md) | [174](/filings/0000950170-25-066934.md) | [156](/filings/0000950170-25-105161.md) | [163](/filings/0001193125-25-270040.md) | [219](/filings/0001193125-26-338401.md) | [214](/filings/0001193125-26-206707.md) | [272](/filings/0001193125-26-338401.md) |
| Total liabilities | $m | [166](/filings/0000950170-23-062243.md) | [173](/filings/0000950170-25-026729.md) | [172](/filings/0000950170-24-057270.md) | [174](/filings/0000950170-24-094193.md) | [170](/filings/0000950170-24-119668.md) | [191](/filings/0001193125-26-066937.md) | [195](/filings/0000950170-25-066934.md) | [177](/filings/0000950170-25-105161.md) | [185](/filings/0001193125-25-270040.md) | [267](/filings/0001193125-26-338401.md) | [264](/filings/0001193125-26-206707.md) | [1,776](/filings/0001193125-26-338401.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,696](/filings/0000950170-24-119668.md) | [1,737](/filings/0001193125-26-066937.md) | [1,782](/filings/0001193125-25-270040.md) | [1,832](/filings/0001193125-25-270040.md) | [1,904](/filings/0001193125-25-270040.md) | [1,926](/filings/0001193125-26-338401.md) | [1,920](/filings/0001193125-26-338401.md) | [1,963](/filings/0001193125-26-338401.md) | [2,002](/filings/0001193125-25-270040.md) | [2,101](/filings/0001193125-26-338401.md) | [2,132](/filings/0001193125-26-338401.md) | [1,923](/filings/0001193125-26-338401.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [28.6 d](/filings/0000950170-24-119668.md) | [61.6 d](/filings/0001193125-26-066937.md) | [57.1](/filings/0000950170-25-066934.md) | [65.3 d](/filings/0000950170-25-105161.md) | [67.2 d](/filings/0001193125-25-270040.md) | [56.0 d](/filings/0001193125-26-066937.md) | [92.0](/filings/0001193125-26-206707.md) | [57.9 d](/filings/0001193125-26-338401.md) | [83.4 d](/filings/0001193125-25-270040.md) | [95.0 d](/filings/0001193125-26-066937.md) | [26.3](/filings/0001193125-26-206707.md) | [61.5 d](/filings/0001193125-26-338401.md) |
| Capital expenditure | $m | [7.6 d](/filings/0000950170-24-119668.md) | [2.5 d](/filings/0001193125-26-066937.md) | [7.0](/filings/0000950170-25-066934.md) | [12.3 d](/filings/0000950170-25-105161.md) | [8.0 d](/filings/0001193125-25-270040.md) | [4.6 d](/filings/0001193125-26-066937.md) | [8.2](/filings/0001193125-26-206707.md) | [13.8 d](/filings/0001193125-26-338401.md) | [1.4 d](/filings/0001193125-25-270040.md) | [5.1 d](/filings/0001193125-26-066937.md) | [3.6](/filings/0001193125-26-206707.md) | [3.7 d](/filings/0001193125-26-338401.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-119668.md) | [0.0 d](/filings/0001193125-26-066937.md) | [0.0](/filings/0000950170-25-066934.md) | [0.0 d](/filings/0000950170-25-105161.md) | [0.0 d](/filings/0001193125-25-270040.md) | [25.1 d](/filings/0001193125-26-066937.md) | [75.0](/filings/0001193125-26-206707.md) | [0.0 d](/filings/0001193125-26-338401.md) | [0.0 d](/filings/0001193125-25-270040.md) | [0.0 d](/filings/0001193125-26-066937.md) | [0.0](/filings/0001193125-26-206707.md) | [205 d](/filings/0001193125-26-338401.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.9](/filings/0000950170-23-062243.md) | [49.1](/filings/0000950170-24-057270.md) | [49.3](/filings/0000950170-24-094193.md) | [49.4](/filings/0000950170-24-119668.md) | [49.6](/filings/0000950170-25-066934.md) | [49.7](/filings/0000950170-25-105161.md) | [49.7](/filings/0001193125-25-270040.md) | [49.4](/filings/0001193125-26-206707.md) | [49.0](/filings/0001193125-26-338401.md) | [49.1](/filings/0001193125-25-270040.md) | [50.0](/filings/0001193125-26-206707.md) | [49.7](/filings/0001193125-26-338401.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,074,247 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338401.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.